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of osteoarthritis
BY JEAN-PIERRE MATTEI AND HUBERT ROUX
Hoˆpital La Conception, Marseille, FranceSINCE changes in the subchondral bone may
initiate damage and progressive deterioration to
cartilage, the sti#ness of the subchondral bone
may contribute to chondrocyte dysfunction and
osteoarthritis (OA). Therefore, the aim of therapy
should be to make the subchondral bone more
able to change its shape on impact loading. This
would result in less force being transmitted to
the cartilage, and fewer lesions in the cartilage.
Unfortunately, there is no magic drug, but there
are several possible treatments which merit
discussion.Genetic factors
Keen [1] demonstrated an association between
Taq 1 polymorphism of the Vitamin D Receptor
(VDR) locus on chromosome 12, and early knee OA
in women. A low serum level and a low intake of
Vitamin D seem to be associated with a risk of
progression of knee OA. This is independent of the
body-mass index, hormone replacement therapy,
the bone mineral density or the age. There is a
three-fold increase in OA in women with the VDR
genotype TT or Tt. This relationship may be linked
to an alteration of the VDR protein, or to a linkage
desequilibrium between Taq 1 polymorphism and
a novel gene disease. Finding this gene would
probably lead to important advances in treatment:
gene replacement therapy or specific treatment
tailored to the molecular cause of the disease.Osteoporosis treatment
There appears to be an inverse relationship
between osteoporosis (OP) and OA, although there
are di#erences depending on which joint is
involved. It is felt it would be interesting to find
out if treatment of OP may be detrimental to OA.
There is no proof that treatment with calcium
supplements, fluoride or bisphosphonates makes
OA worse. However, a low serum level and low329intake of vitamin D seem to be associated with a
risk of progression of OA of the knee. This may be
through the influence of vitamin D on calcium
metabolism, chondrocyte activity, and the regula-
tion of the transition of cartilage to bone at the
growth plate.
Physical activity can increase bone mineral
density, and only seems to be detrimental to joints
that are already damaged. Hormone replacement
therapy (HRT) seems to be beneficial for the knees
in post-menopausal women [2], but may not be
good for the hands in younger patients [3]. The
mechanisms are open to speculation; for example,
a possible factor may be modification of the sti#-
ness of the subchondral bone. Longitudinal studies
are required, with particular interest in the dura-
tion of HRT consumption. Insulin-like growth
factor (IGF)-1, if it is ever used (it may be too
toxic), may have the potential to worsen OA. IGF-1
is increased in subchondral OA [4].Symptoms modifying osteoarthritis drugs
(SMOADs)
Analgesics, nonsteroidal antiinflammatory
drugs (NSAIDs), and the new specific COX2 inhibi-
tors (celecoxib, refecoxib) which appear to o#er
better tolerance, do not appear to have a direct
e#ect at the subchondral level. This is also true
of the slow acting symptom modifying drugs
(SASYMOAD) such as diacerrhein, chondroitine
sulphate, avocado/soya bean unsaponifiables,
glucosamine sulphate, etc.Disease modifying osteoarthritis drugs
(DMOADs)
Tetracyclines (Yu 1996), tenidap, and matrix
metalloprotease inhibitors (such as RO 323555)
seem to be devoid of a direct e#ect at the level
of the subchondral bone, but it should be noted
that there is evidence for increased matrix
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in the subchondral bone [5]. Viscosupplementation
(Hyalgan, Orthovisc, Synvisc, Artz etc.) appears
mainly e#ective at the level of the cartilage to
reduce damage to injected joints in animals. These
agents may also protect the subchondral bone from
excessive stress. Support stem from a lowered
osteoid volume.Other procedures
Therapeutic exercises, weight reduction, walk-
ing aids, hot and cold, electrotherapy, ultrasound,
acupuncture, and hydrotherapy require evalu-
ation. These are unlikely to modify the sub-
chondral bone directly. There may be a place for
neuropeptides [6], since thin porous subchondral
bone was shown to develop following dorsal root
gangliotectomy and anterior cruciate ligament
section in the dog. Similarly, it seems [7] that
subchondral bone cells from patients with OA may
influence cartilage metabolism, and so antagonists
to certain products, for example IGF-1 and
transforming growth factor (TGF)-â [8] may be of
interest.
The idea that subchondral bone may contribute
to the onset and progression of OA is supported
from: 1) observed increased levels of urokinase
plasminogen activator and IGF-1 in explants from
subchondral bone, and 2) the increased production
of alkaline phosphatase and osteocalcin in
osteoblast-like cultures with and without VitaminD stimulation (Hilal 1998). Subchondral bone
appears to be potential target for new treatments
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